CellSource Co., Ltd. (4880.T)
JPY 844.0
(-1.97%)
JPY 844.0
(-1.97%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 97.54 Million JPY | 0.0% |
| 2022 | - JPY | -100.0% |
| 2021 | 1.09 Million JPY | -74.4% |
| 2020 | 4.28 Million JPY | -41.49% |
| 2019 | 7.32 Million JPY | 0.0% |
| 2018 | - JPY | 0.0% |
| 2017 | - JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | - JPY | -100.0% |
| 2024 Q2 | 67.04 Million JPY | -7.09% |
| 2024 Q1 | 72.16 Million JPY | -26.02% |
| 2023 Q4 | 97.54 Million JPY | 0.0% |
| 2023 FY | 97.54 Million JPY | 0.0% |
| 2023 Q3 | - JPY | 0.0% |
| 2023 Q2 | - JPY | 0.0% |
| 2023 Q1 | - JPY | 0.0% |
| 2022 Q2 | 11 Million JPY | 0.0% |
| 2022 Q1 | 11 Million JPY | 902.73% |
| 2022 Q4 | - JPY | 0.0% |
| 2022 FY | - JPY | -100.0% |
| 2022 Q3 | - JPY | -100.0% |
| 2021 Q1 | - JPY | -100.0% |
| 2021 Q2 | - JPY | 0.0% |
| 2021 Q3 | 11 Million JPY | 0.0% |
| 2021 Q4 | 1.09 Million JPY | -90.03% |
| 2021 FY | 1.09 Million JPY | -74.4% |
| 2020 FY | 4.28 Million JPY | -41.49% |
| 2020 Q1 | - JPY | -100.0% |
| 2020 Q4 | 4.28 Million JPY | 0.0% |
| 2020 Q3 | - JPY | 0.0% |
| 2020 Q2 | - JPY | 0.0% |
| 2019 Q3 | - JPY | 0.0% |
| 2019 Q4 | 7.32 Million JPY | 0.0% |
| 2019 FY | 7.32 Million JPY | 0.0% |
| 2018 FY | - JPY | 0.0% |
| 2017 FY | - JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 2.46 Billion JPY | 96.05% |
| PRISM BioLab Co.,LTD | - JPY | -Infinity% |
| GNI Group Ltd. | 3.69 Billion JPY | 97.363% |
| Linical Co., Ltd. | 3 Billion JPY | 96.751% |
| Trans Genic Inc. | 2.25 Billion JPY | 95.678% |
| MEDINET Co., Ltd. | 2.3 Million JPY | -4128.088% |
| Soiken Holdings Inc. | - JPY | -Infinity% |
| Cytori Cell Research Institute, Inc. | 2.47 Billion JPY | 96.054% |
| AnGes, Inc. | 362.67 Million JPY | 73.105% |
| OncoTherapy Science, Inc. | 106.84 Million JPY | 8.71% |
| Nxera Pharma Co., Ltd. | 73.97 Billion JPY | 99.868% |
| Immuno-Biological Laboratories Co., Ltd. | 235.98 Million JPY | 58.665% |
| NanoCarrier Co., Ltd. | 1.1 Billion JPY | 91.204% |
| Carna Biosciences, Inc. | 182.97 Million JPY | 46.69% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 885.12 Million JPY | 88.98% |
| RaQualia Pharma Inc. | 367.71 Million JPY | 73.474% |
| Chiome Bioscience Inc. | 291 Million JPY | 66.48% |
| Kidswell Bio Corporation | 2.57 Billion JPY | 96.212% |
| PeptiDream Inc. | 22.79 Billion JPY | 99.572% |
| Oncolys BioPharma Inc. | 315.17 Million JPY | 69.051% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | 665 Million JPY | 85.332% |
| Healios K.K. | 4.53 Billion JPY | 97.848% |
| BrightPath Biotherapeutics Co., Ltd. | 112.5 Million JPY | 13.296% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 142.85 Million JPY | 31.719% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| FunPep Company Limited | - JPY | -Infinity% |
| Kringle Pharma, Inc. | - JPY | -Infinity% |
| Stella Pharma Corporation | 933.3 Million JPY | 89.549% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | - JPY | -Infinity% |
| Cuorips Inc. | - JPY | -Infinity% |
| K Pharma,Inc. | - JPY | -Infinity% |
| Takara Bio Inc. | 968 Million JPY | 89.923% |
| ReproCELL Incorporated | - JPY | -Infinity% |
| PhoenixBio Co., Ltd. | 723.93 Million JPY | 86.526% |
| StemCell Institute Inc. | 8.78 Million JPY | -1010.451% |
| Japan Tissue Engineering Co., Ltd. | - JPY | -Infinity% |
| CellSeed Inc. | 151.25 Million JPY | 35.509% |